JP2002507600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002507600A5 JP2002507600A5 JP2000537853A JP2000537853A JP2002507600A5 JP 2002507600 A5 JP2002507600 A5 JP 2002507600A5 JP 2000537853 A JP2000537853 A JP 2000537853A JP 2000537853 A JP2000537853 A JP 2000537853A JP 2002507600 A5 JP2002507600 A5 JP 2002507600A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- embedded image
- compound
- here
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC([C@](*)CC(CCC1)CN1C(N)=N)NC(c(cc1)ccc1-c1ccccc1)=O Chemical compound CC([C@](*)CC(CCC1)CN1C(N)=N)NC(c(cc1)ccc1-c1ccccc1)=O 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- -1 phenyl-substituted phenyl Chemical group 0.000 description 4
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- YALBSZKTUKJWQM-UHFFFAOYSA-N 1-N,1-N-diethyl-2-N,2-N',2-N'-trimethylpyrrolidine-1,2,2,3-tetramine Chemical compound NC1C(N(CC1)N(CC)CC)(N(C)C)NC YALBSZKTUKJWQM-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- JJFLDHBSMPNEPU-IVAFLUGOSA-N CC([C@@H](CC(CC1)=CCN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O Chemical compound CC([C@@H](CC(CC1)=CCN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O JJFLDHBSMPNEPU-IVAFLUGOSA-N 0.000 description 1
- CLYMUWFQNFEMJT-IVAFLUGOSA-N CC([C@@H](CC1CCNCC1)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O Chemical compound CC([C@@H](CC1CCNCC1)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O CLYMUWFQNFEMJT-IVAFLUGOSA-N 0.000 description 1
- FSAURURHTUEOLY-PAHOBDAQSA-N CCC([C@@H](CC(CCC1)CN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1cc(CN)ccc1)=O Chemical compound CCC([C@@H](CC(CCC1)CN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1cc(CN)ccc1)=O FSAURURHTUEOLY-PAHOBDAQSA-N 0.000 description 1
- MQCUMGNIFMPZGY-FQLXRVMXSA-N COC([C@H](CCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1C1=CC=CNC1)=O)=O Chemical compound COC([C@H](CCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1C1=CC=CNC1)=O)=O MQCUMGNIFMPZGY-FQLXRVMXSA-N 0.000 description 1
- GLFPUJSRGLHTNJ-KCUXUGRMSA-N COC([C@H](CCCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1-c1cccnc1)O)=O Chemical compound COC([C@H](CCCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1-c1cccnc1)O)=O GLFPUJSRGLHTNJ-KCUXUGRMSA-N 0.000 description 1
- FQJFKKBSQSSURN-RMRANGLJSA-N C[C@H]([C@@H](CC1CNCCC1)C(OC)=O)NC(c(cc1)ccc1-c1ncccc1)=O Chemical compound C[C@H]([C@@H](CC1CNCCC1)C(OC)=O)NC(c(cc1)ccc1-c1ncccc1)=O FQJFKKBSQSSURN-RMRANGLJSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000005542 phthalazyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7900298P | 1998-03-23 | 1998-03-23 | |
| US60/079,002 | 1998-03-23 | ||
| PCT/US1999/006224 WO1999048870A1 (en) | 1998-03-23 | 1999-03-22 | Piperididinyl and n-amidinopiperidinyl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002507600A JP2002507600A (ja) | 2002-03-12 |
| JP2002507600A5 true JP2002507600A5 (enExample) | 2006-05-18 |
| JP4495339B2 JP4495339B2 (ja) | 2010-07-07 |
Family
ID=22147579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000537853A Expired - Fee Related JP4495339B2 (ja) | 1998-03-23 | 1999-03-22 | ピペリジニルおよびｎ−アミジノピペリジニル誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6277865B1 (enExample) |
| EP (1) | EP1080075B1 (enExample) |
| JP (1) | JP4495339B2 (enExample) |
| KR (1) | KR20010042125A (enExample) |
| CN (1) | CN1297440A (enExample) |
| AT (1) | ATE273277T1 (enExample) |
| AU (1) | AU757868B2 (enExample) |
| BR (1) | BR9909086A (enExample) |
| CA (1) | CA2325471C (enExample) |
| DE (1) | DE69919349T2 (enExample) |
| ES (1) | ES2224620T3 (enExample) |
| HU (1) | HUP0101482A3 (enExample) |
| PL (1) | PL344056A1 (enExample) |
| TR (1) | TR200002740T2 (enExample) |
| WO (1) | WO1999048870A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002233206B2 (en) * | 2000-12-06 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Guanidine and amidine derivatives as factor xa inhibitors |
| DE10124041A1 (de) * | 2001-05-16 | 2002-11-21 | Graffinity Pharm Design Gmbh | Protease Inhibitoren |
| CA2507707C (en) | 2002-12-03 | 2011-06-21 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| DK3026044T3 (en) | 2006-06-26 | 2019-02-18 | Akebia Therapeutics Inc | PROLYL HYDROXYLASE INHIBITORS AND METHODS FOR USE |
| MX2013014310A (es) | 2011-06-06 | 2014-01-23 | Akebia Therapeutics Inc | Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer. |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| EP2759533B1 (en) | 2011-09-22 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| DK3007695T3 (da) | 2013-06-13 | 2024-03-18 | Akebia Therapeutics Inc | Sammensætninger og fremgangsmåder til behandling af anæmi |
| SG10202012791TA (en) | 2013-11-15 | 2021-01-28 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| MX2017009417A (es) | 2015-01-23 | 2017-12-07 | Akebia Therapeutics Inc | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. |
| PT3277270T (pt) | 2015-04-01 | 2021-12-07 | Akebia Therapeutics Inc | Composições e métodos de tratamento de anemia |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916145A (en) * | 1987-07-10 | 1990-04-10 | Hoffmann-La Roche Inc. | Substituted n-[(pyridyl)alkyl]aryl-carboxamide |
| GB9107043D0 (en) * | 1991-04-04 | 1991-05-22 | Pfizer Ltd | Therapeutic agents |
| WO1994012181A1 (en) * | 1992-12-01 | 1994-06-09 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5583146A (en) * | 1992-12-02 | 1996-12-10 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
| DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| US5658930A (en) * | 1994-12-13 | 1997-08-19 | Corvas International, Inc. | Aromatic heterocyclic derivatives as enzyme inhibitors |
| DE69526677T2 (de) * | 1994-12-13 | 2002-12-05 | Corvas International, Inc. | Aromatische heterocyclische derivate als enzyminhibitoren |
| DE19502644A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | 4-Amino-benzoylguanidin-Derivate |
| PL325954A1 (en) * | 1995-09-29 | 1998-08-17 | Dimiensional Pharmaceuticals 3 | Guanidinic protease inhibitors |
| US5852045A (en) * | 1995-10-19 | 1998-12-22 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| EP0866705A4 (en) * | 1995-10-19 | 1999-03-03 | Merck & Co Inc | FIBRINOGENIC RECEPTOR ANTAGONISTS |
| CZ297544B6 (cs) * | 1996-01-02 | 2007-02-07 | Aventis Pharmaceuticals Inc. | Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy |
| US5668289A (en) * | 1996-06-24 | 1997-09-16 | Merck & Co., Inc. | Pyridinone thrombin inhibitors |
-
1999
- 1999-03-22 CN CN99805060A patent/CN1297440A/zh active Pending
- 1999-03-22 US US09/273,618 patent/US6277865B1/en not_active Expired - Lifetime
- 1999-03-22 AU AU31094/99A patent/AU757868B2/en not_active Ceased
- 1999-03-22 AT AT99912798T patent/ATE273277T1/de not_active IP Right Cessation
- 1999-03-22 WO PCT/US1999/006224 patent/WO1999048870A1/en not_active Ceased
- 1999-03-22 TR TR2000/02740T patent/TR200002740T2/xx unknown
- 1999-03-22 PL PL99344056A patent/PL344056A1/xx unknown
- 1999-03-22 CA CA2325471A patent/CA2325471C/en not_active Expired - Fee Related
- 1999-03-22 KR KR1020007010524A patent/KR20010042125A/ko not_active Withdrawn
- 1999-03-22 DE DE1999619349 patent/DE69919349T2/de not_active Expired - Lifetime
- 1999-03-22 EP EP99912798A patent/EP1080075B1/en not_active Expired - Lifetime
- 1999-03-22 ES ES99912798T patent/ES2224620T3/es not_active Expired - Lifetime
- 1999-03-22 HU HU0101482A patent/HUP0101482A3/hu unknown
- 1999-03-22 BR BR9909086-4A patent/BR9909086A/pt not_active IP Right Cessation
- 1999-03-22 JP JP2000537853A patent/JP4495339B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002507600A5 (enExample) | ||
| CA2336952A1 (en) | 5-thia-.omega.-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient | |
| KR960704851A (ko) | 면역억제제로서 유용한 카보사이클과 헤테로사이클이 융합된-고리 퀴놀린카복실산 (carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents) | |
| JP2021519766A (ja) | ＸＩＩａ因子インヒビター | |
| JP2005501120A5 (enExample) | ||
| JP2004531517A5 (enExample) | ||
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| CA2413313A1 (en) | Antitumor effect potentiators | |
| JP2007511487A5 (enExample) | ||
| CA2597069A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| JP2021523887A (ja) | ＸＩＩａ因子インヒビター | |
| HUE034869T2 (en) | Combination therapy with substituted oxazolidinones | |
| KR20170055531A (ko) | 에스지씨 자극제 | |
| JP2009521472A (ja) | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト | |
| RU2002130247A (ru) | Производные оксадиазола, обладающие противоопухолевым действием | |
| CA2149691A1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
| JP2000506170A (ja) | 酸化窒素スキャベンジャーを用いる複合治療方法とそのために有用な組成物 | |
| JP2003522768A5 (enExample) | ||
| JP2003535890A (ja) | アクリロイルジスタマイシン誘導体並びにトポイソメラーゼｉ及びｉｉ阻害剤を含む薬剤組成物 | |
| JP2021102653A5 (enExample) | ||
| EP1190714A2 (en) | Method for the treatment of thromboembolic disorders in patients with aspirin resistance | |
| JP4175887B2 (ja) | 新規血管狭窄治療剤または予防剤 | |
| JP2000103736A (ja) | 血管透過性亢進抑制剤 | |
| JP2838282B2 (ja) | 血管攣縮治療剤 | |
| RS53896B1 (sr) | Pantenil dokosaheksaenoat i njegova upotreba za lečenje i prevenciju kardiovaskularnih oboljenja |